Biotech News

AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference

AN2 Therapeutics (ANTX)AN2 TherapeuticsConference / presentation

MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 20, 2026-- AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom,

Related news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...

Recent company news

Stock data

Close
5.22 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States